Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Heart Valve Disease

Background:

• Functional mitral regurgitation (FMR) management is complex.
• Two pivotal 2018 trials, MITRA-FR and COAPT, investigating the MitraClip device for FMR presented conflicting outcomes.
• This discrepancy created significant uncertainty in clinical practice and research.

Purpose of the Study:

• To analyze the divergent findings between the MITRA-FR and COAPT trials.
• To identify key differentiating factors that may explain the contrasting results.
• To provide clarity on the optimal use of percutaneous mitral valve repair for FMR.

Main Methods:

• Comparative analysis of trial methodologies and patient populations.
• Examination of differences in effective regurgitant orifice area (EROA) and echocardiographic parameters.
• Review of guideline-directed medical therapy (GDMT) intensity and patient selection criteria.

Main Results:

• Significant differences were observed in EROA, GDMT, and patient selection criteria between MITRA-FR and COAPT.
• These factors, alongside technical procedural nuances, likely contributed to the disparate trial outcomes.
• The analysis highlights the critical importance of precise patient selection and echocardiographic assessment.

Conclusions:

• The contrasting results of MITRA-FR and COAPT underscore the need for careful consideration of patient-specific factors in FMR treatment.
• Understanding these differences is crucial for optimizing the application of percutaneous mitral valve repair devices like the MitraClip.
• Further research should focus on refining patient selection and defining the role of MitraClip in various FMR phenotypes.